Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove

  1. Curtis McMurtrey
  2. Thomas Trolle
  3. Tiffany Sansom
  4. Soumya G Remesh
  5. Thomas Kaever
  6. Wilfried Bardet
  7. Kenneth Jackson
  8. Morten Nielsen
  9. Rima McLeod
  10. Dirk M Zajonc
  11. Ira J Blader
  12. Bjoern Peters
  13. Alessandro Sette
  14. William Hildebrand  Is a corresponding author
  1. University of Oklahoma Health Sciences Center, United States
  2. Technical University of Denmark, Denmark
  3. University at Buffalo School of Medicine, United States
  4. La Jolla Institute for Allergy and Immunology, United States
  5. University of Chicago, United States
  6. University of Oklahoma Health Science Center, United States

Abstract

HLA class I presentation of pathogen-derived peptide ligands is essential for CD8+ T-cell recognition of Toxoplasma gondii infected cells. Currently, little data exist pertaining to peptides that are presented after T. gondii infection. Herein we purify HLA-A*02:01 complexes from T. gondii infected cells and characterize the peptide ligands using LCMS. We identify 195 T. gondii encoded ligands originating from both secreted and cytoplasmic proteins. Surprisingly, T. gondii ligands are significantly longer than uninfected host ligands, and these longer pathogen-derived peptides maintain a canonical N-terminal binding core yet exhibit a C-terminal extension of 1-30 amino acids. Structural analysis demonstrates that binding of extended peptides opens the HLA class I F' pocket, allowing the C-terminal extension to protrude through one end of the binding groove. In summary, we demonstrate that unrealized structural flexibility makes MHC class I receptive to parasite-derived ligands that exhibit unique C-terminal peptide extensions.

Article and author information

Author details

  1. Curtis McMurtrey

    Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Thomas Trolle

    Center for Biological Sequence Analysis, Technical University of Denmark, Kongens Lyngby, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  3. Tiffany Sansom

    Department of Microbiology and Immunology, University at Buffalo School of Medicine, Buffalo, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Soumya G Remesh

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Thomas Kaever

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Wilfried Bardet

    Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Kenneth Jackson

    Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Morten Nielsen

    Center for Biological Sequence Analysis, Technical University of Denmark, Kongens Lyngby, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  9. Rima McLeod

    University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Dirk M Zajonc

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Ira J Blader

    Department of Microbiology and Immunology, University at Buffalo School of Medicine, Buffalo, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Bjoern Peters

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Alessandro Sette

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. William Hildebrand

    Department of Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, United States
    For correspondence
    william-hildebrand@ouhsc.edu
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2016, McMurtrey et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,312
    views
  • 497
    downloads
  • 68
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Curtis McMurtrey
  2. Thomas Trolle
  3. Tiffany Sansom
  4. Soumya G Remesh
  5. Thomas Kaever
  6. Wilfried Bardet
  7. Kenneth Jackson
  8. Morten Nielsen
  9. Rima McLeod
  10. Dirk M Zajonc
  11. Ira J Blader
  12. Bjoern Peters
  13. Alessandro Sette
  14. William Hildebrand
(2016)
Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove
eLife 5:e12556.
https://doi.org/10.7554/eLife.12556

Share this article

https://doi.org/10.7554/eLife.12556

Further reading

    1. Immunology and Inflammation
    Aryeh Solomon, Noa Bossel Ben-Moshe ... Roi Avraham
    Research Article

    Trained immunity (TI) is the process wherein innate immune cells gain functional memory upon exposure to specific ligands or pathogens, leading to augmented inflammatory responses and pathogen clearance upon secondary exposure. While the differentiation of hematopoietic stem cells (HSCs) and reprogramming of bone marrow (BM) progenitors are well-established mechanisms underpinning durable TI protection, remodeling of the cellular architecture within the tissue during TI remains underexplored. Here, we study the effects of peritoneal Bacillus Calmette–Guérin (BCG) administration to find TI-mediated protection in the spleen against a subsequent heterologous infection by the Gram-negative pathogen Salmonella Typhimurium (S.Tm). Utilizing single cell RNA-sequencing and flow cytometry, we discerned STAT1-regulated genes in TI-associated resident and recruited splenic myeloid populations. The temporal dynamics of TI were further elucidated, revealing both early and delayed myeloid subsets with time-dependent, cell-type-specific STAT1 signatures. Using lineage tracing, we find that tissue-resident red pulp macrophages (RPM), initially depleted by BCG exposure, are restored from both tissue-trained, self-renewing macrophages and from bone marrow-derived progenitors, fostering long lasting local defense. Early inhibition of STAT1 activation, using specific JAK-STAT inhibitors, reduces both RPM loss and recruitment of trained monocytes. Our study suggests a temporal window soon after BCG vaccination, in which STAT1-dependent activation of long-lived resident cells in the tissue mediates localized protection.

    1. Immunology and Inflammation
    Yalan Jiang, Pingping He ... Xiaoou Shan
    Research Article

    Type 1 diabetes mellitus (T1DM), known as insulin-dependent diabetes mellitus, is characterized by persistent hyperglycemia resulting from damage to the pancreatic β cells and an absolute deficiency of insulin, leading to multi-organ involvement and a poor prognosis. The progression of T1DM is significantly influenced by oxidative stress and apoptosis. The natural compound eugenol (EUG) possesses anti-inflammatory, anti-oxidant, and anti-apoptotic properties. However, the potential effects of EUG on T1DM had not been investigated. In this study, we established the streptozotocin (STZ)-induced T1DM mouse model in vivo and STZ-induced pancreatic β cell MIN6 cell model in vitro to investigate the protective effects of EUG on T1DM, and tried to elucidate its potential mechanism. Our findings demonstrated that the intervention of EUG could effectively induce the activation of nuclear factor E2-related factor 2 (NRF2), leading to an up-regulation in the expressions of downstream proteins NQO1 and HMOX1, which are regulated by NRF2. Moreover, this intervention exhibited a significant amelioration in pancreatic β cell damage associated with T1DM, accompanied by an elevation in insulin secretion and a reduction in the expression levels of apoptosis and oxidative stress-related markers. Furthermore, ML385, an NRF2 inhibitor, reversed these effects of EUG. The present study suggested that EUG exerted protective effects on pancreatic β cells in T1DM by attenuating apoptosis and oxidative stress through the activation of the NRF2 signaling pathway. Consequently, EUG holds great promise as a potential therapeutic candidate for T1DM.